Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →

Help us improve your experience. Please confirm your investor type:

Compare ETFs Easily

The Ultimate ETF Comparison Tool - Try Now!

Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.

GNMX

Corgi Genomics & Precision Medicine ETF

The GNMX Exchange Traded Fund (ETF) is provided by Corgi Funds. This fund is actively managed; it does not track an index. This share class generates a stream of income by distributing dividends.

Advertisement

Advertisement

$32.12
N/A
Data as of 08/18/26
1D price range
N/A
52W price range
$24.04$32.41
YTD Perf.
+25.05%
YTD Flows
Annualized volatility
Fund AuM
€1.2M
Share class AuM
€1.2M
TTM Yield
Tracking Error
Tracking Difference
ISIN
US2189468463
TER
0.35%
Inception date
5/6/2026
Dividend policy
Compare similar ETFs
API
PerformanceJul 31, 2026 - Aug 18, 2026
0%2%4%6%8%10%Jul 31Aug 3Aug 4Aug 5Aug 6Aug 7Aug 10Aug 11Aug 12Aug 13Aug 14Aug 17Aug 18
Flows
Join for free to unlock
Data as of 06/30/26
Healthcare
98.21%
Unavailable
1.79%
Latest GNMX news

No content available for this fund

FAQ about GNMX

GNMX is a Active ETF. This ETF provides exposure to Other Equities.
GNMX carries a total expense ratio (TER) of 0.35%, indicating the annual cost for holding the fund.
GNMX was introduced to the market on May 6, 2026. It trades on United States
Corgi Genomics & Precision Medicine ETF, GNMX, is provided by Corgi Funds. Learn more about Corgi Funds here.
GNMX oversees €1.2M in assets as of August 18, 2026.
GNMX follows a distributing dividend policy, meaning it pays out income to investors.
As of June 30, 2026, GNMX has significant geographic allocations in USA, Netherlands and Denmark.
As of June 30, 2026, GNMX focuses largely on Healthcare.
As of June 30, 2026, GNMX holds 57 positions in its portfolio, with 53.10% of assets concentrated in its top 15 holdings.
As of June 30, 2026, GNMX top three holdings include Thermo Fisher Scientific, Inc., Vertex Pharmaceuticals, Inc. and Guardant Health, Inc..
The base currency of GNMX is USD.
Data as of 06/30/26
Thermo Fisher Scientific, Inc.
7.80%
Vertex Pharmaceuticals, Inc.
6.73%
Guardant Health, Inc.
3.85%
Illumina, Inc.
3.84%
Revolution Medicines, Inc.
3.83%
Alnylam Pharmaceuticals, Inc.
3.77%
Moderna, Inc.
3.71%
Incyte Corp.
3.09%
Genmab A/S
2.54%
Bio-Techne Corp.
2.50%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight